The cancer-associated PTPN11 mutations target two hotspots at the N-SH2 and PTP domains, respectively (Figure 3), that mostly result in an increased phosphatase activity or in a reduced threshold for SHP2 activation (Chan et al., 2008; Zhang et al., 2015). Here, PTPRU is linked to cancer.